z-logo
open-access-imgOpen Access
Pleomorphic adenoma of the lacrimal gland: atypical location of a salivary tumor
Author(s) -
Araceli Gómez Rosso,
María Elena Samar,
Ávila Rodolfo,
Luis Ferraris,
Ismael Bernardo Fonseca,
Javier Elías Fernández
Publication year - 2020
Publication title -
revista de la facultad de odontología
Language(s) - English
Resource type - Journals
eISSN - 2545-7594
pISSN - 0325-1071
DOI - 10.25014/revfacodont271.2020.30.3.20
Subject(s) - pleomorphic adenoma , lacrimal gland , pathology , adenoma , medicine , immunostaining , immunohistochemistry , salivary gland , h&e stain , histopathology , benign tumor
In daily ophthalmological practice, lacrimal gland tumors are rare. They represent 5 to 7.5% of all intraorbital tumors. The most common epithelial tumor of this gland is the pleomorphic adenoma, with a percentage of 25 to 50% of its tumor lesions. Objective: In this communication we presented a case of lacrimal gland pleomorphic adenoma and study the expression of Ki67 and the location and expression of MUC-1 and its correlation with tumor prognosis. We also carried out a retrospective descriptive study of the literature on the subject published between 1951 and 2020, using the MEDLINE database. Material and methods: The surgical piece examined, was processed according to the paraffin embedding technique, was performed with a histopathological diagnosis of pleomorphic lacrimal gland adenoma. Histological sections were stained with Hematoxylin / Eosin. Immunostaining with Ki67 and MUC-1 was performed with the DAKO LSAB + kit. Results: The diagnosis of hypercellular pleomorphic adenoma with areas of the remaining lacrimal gland was made. Ki67 labeling was low (≤15%). MUC-1 expression was intense, situated to the apical cell membrane of approximately 10% epitheliocytes from pseudoductal and cystic structures.Conclusions: Through histopathological evaluation, the correlation of Ki67 expression and the location and expression of MUC1, we verified that it is a non-recurrent pleomorphic adenoma without malignant transformation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here